Bengaluru: Vaccine Manufacturer Bharat Biotech On Friday, the Russia-Ukraine conflict had not affected the company’s supply chain so far.
Unlike many Western companies, including McDonald’s, Microsoft, Coca-Cola and Starbucks, which have ceased sales or operations in Russia, no Indian company has publicly withdrawn from the region.
Some Indian pharmaceutical companies are present in Russia, which export and sell medicines in the country. Between April and December last year, sales to Russia reached $386 million, or 15% of the country’s total exports.
Dr Reddy’s Laboratories said on Wednesday it was focused on business continuity in and around Russia, while officials at Torrent Pharma and Zydus Lifesciences said they saw little or no impact on sales due to the conflict.
Production of indigenous Kovid-19 vaccine of Bharat Biotech covaxin “While completely indigenous, all (active pharmaceutical ingredients) and critical raw materials are manufactured within India,” the company said in an emailed statement.
It was always a strategic decision at Bharat Biotech to develop and commercialize technologies developed within India and reduce dependence on external sources.
Bharat Biotech’s Covid-19 shot Covaxin has accounted for 16.5% of the nearly 1.80 billion vaccine doses delivered to the Indian population so far.
Unlike many Western companies, including McDonald’s, Microsoft, Coca-Cola and Starbucks, which have ceased sales or operations in Russia, no Indian company has publicly withdrawn from the region.
Some Indian pharmaceutical companies are present in Russia, which export and sell medicines in the country. Between April and December last year, sales to Russia reached $386 million, or 15% of the country’s total exports.
Dr Reddy’s Laboratories said on Wednesday it was focused on business continuity in and around Russia, while officials at Torrent Pharma and Zydus Lifesciences said they saw little or no impact on sales due to the conflict.
Production of indigenous Kovid-19 vaccine of Bharat Biotech covaxin “While completely indigenous, all (active pharmaceutical ingredients) and critical raw materials are manufactured within India,” the company said in an emailed statement.
It was always a strategic decision at Bharat Biotech to develop and commercialize technologies developed within India and reduce dependence on external sources.
Bharat Biotech’s Covid-19 shot Covaxin has accounted for 16.5% of the nearly 1.80 billion vaccine doses delivered to the Indian population so far.